Summit Therapeutics Files 8-K Report
Ticker: SMMT · Form: 8-K · Filed: May 30, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
TL;DR
Summit Therapeutics filed an 8-K, likely containing routine updates. No major news yet.
AI Summary
On May 30, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Miami, FL.
Why It Matters
This 8-K filing indicates that Summit Therapeutics Inc. has submitted required regulatory documentation to the SEC, which may contain updates or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- May 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Miami, FL (location) — Principal Executive Offices
- 001-36866 (other) — SEC File Number
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item information category.
When was Summit Therapeutics Inc. incorporated?
Summit Therapeutics Inc. was incorporated in Delaware, as indicated by the filing.
What is the primary business classification for Summit Therapeutics Inc.?
Summit Therapeutics Inc. falls under the Standard Industrial Classification code 2834, which is for Pharmaceutical Preparations.
Where are Summit Therapeutics Inc.'s principal executive offices located?
The principal executive offices of Summit Therapeutics Inc. are located at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
What is the SEC file number for Summit Therapeutics Inc.?
The SEC file number for Summit Therapeutics Inc. is 001-36866.
Filing Stats: 460 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-05-30 16:48:30
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240530.htm (8-K) — 29KB
- a2024_prx0530xivonescima.htm (EX-99.1) — 19KB
- a2024_prx0530xivonescima001.jpg (GRAPHIC) — 253KB
- a2024_prx0530xivonescima002.jpg (GRAPHIC) — 254KB
- a2024_prx0530xivonescima003.jpg (GRAPHIC) — 210KB
- a2024_prx0530xivonescima004.jpg (GRAPHIC) — 214KB
- a2024_prx0530xivonescima005.jpg (GRAPHIC) — 196KB
- a2024_prx0530xivonescima006.jpg (GRAPHIC) — 97KB
- 0001599298-24-000096.txt ( ) — 1894KB
- smmt-20240530.xsd (EX-101.SCH) — 2KB
- smmt-20240530_def.xml (EX-101.DEF) — 14KB
- smmt-20240530_lab.xml (EX-101.LAB) — 25KB
- smmt-20240530_pre.xml (EX-101.PRE) — 15KB
- smmt-20240530_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On May 30, 2024, Summit Therapeutics Inc. (the "Company") issued a press release announcing that Monotherapy Ivonescimab achieved clinically meaningful progression-free survival (PFS) benefit in the Phase III clinical trial, HARMONi-2 or AK112-303, conducted in China, sponsored by Akeso, Inc. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press R elease, dated May 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: May 30, 2024 By: /s/ Manmeet S. Soni Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)